Publication date: Dec 09, 2024
The respiratory rate-oxygenation (ROX) index is used to predict high-flow nasal cannula (HFNC) success in acute respiratory failure, including in Coronavirus disease 2019 (COVID-19) patients. However, no study has described its performance to predict failure of alternating sessions of noninvasive ventilation (NIV) and HFNC in severe COVID-19 patients. We conducted a monocentric retrospective cohort study. COVID-19 patients admitted in the intensive care unit (ICU) for acute respiratory failure were treated by alternating sessions of HFNC and NIV. The primary endpoint was the ability for ROX index at 2 hours (h) of NIV initiation to predict HFNC/NIV failure defined by orotracheal intubation (OTI) within 7 days after noninvasive support initiation. One hundred and five patients were included in analysis, of which 47% (n = 49) required OTI by day seven. ROX index values were significantly lower in intubated group at all time points but 24 h. In multivariate analysis, a ROX index at 2 h 
| Concepts | Keywords |
|---|---|
| Coronavirus | coronavirus disease 2019 |
| Hours | mechanical ventilation |
| Orotracheal | noninvasive ventilation |
| Respiratory | ROX index |
| Retrospective |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Respiratory Failure |
| drug | DRUGBANK | Spinosad |
| disease | MESH | Coronavirus disease 2019 |